GSTM1 and axial length measurement: We observed statistically significant decreases in Hb (g/dL)—10.77 ± 2.48—and Ht (%)—33.03 ± 7.37—in patients with AL with CVRFs, compared to Hb values of (g/dL) 13.04 ± 1.69 and Ht (%) 39.72 ± 4.52 in control patients with CVRFs, prior to the initiation of treatment (p < 0.001).